Sponsored by Commercialization at UHN since 2003 and awarded annually, the Inventor of the Year Award (IOTY) recognizes an individual or team whose invention has made a substantial and noteworthy commercialization contribution leading to a healthier world.
Thanks to our world-class researchers, scientists and clinicians, UHN is Canada’s leading medical research hospital and is included within the top 10 North American research hospitals in commercialization (Source: AUTM Licensing Survey).
Commercialization potential of inventions
Commercialization ability, efforts and achievements of the Nominee
Patient Impact/Social Benefit
Drs. Heather Ross and Joseph A. Cafazzo named 2022 joint Inventors of the Year for revolutionizing cardiac care through Medly, a digital health solution for heart health care from anywhere.
Medly reduces heart failure management costs and hospitalizations by 50% and forms the basis of a new UHN venture, Medly Therapeutics, poised to bring heart care benefits to patients around the world.
Scott Bratman and Daniel De Carvalho are the joint winners of UHN’s 18th annual inventor of the Year Award for their contribution to building the next generation of cancer diagnostics. They received the award for their work on advancing a specialized form of circulating tumour DNA (ctDNA) technology, known as cfMeDIP-seq.
cfMeDIP-seq is an ultra-sensitive cell-free DNA methylation pattern detection technology being developed to spot different types of cancers via liquid biopsy. Powered by AI, cfMeDIP-seq is now transforming the landscape of cancer diagnosis and disease management.